![](/img/cover-not-exists.png)
Serum Tenascin-C is independently associated with increased major adverse cardiovascular events and death in patients with type II diabetes
Gellen, B., Thorin-Trescases, N., Thorin, E., Gand, E., Sosner, P., Brishoual, S., Fraty, M., Hadjadj, S., Saulnier, P.J.Volume:
12
Journal:
Archives of Cardiovascular Diseases Supplements
DOI:
10.1016/j.acvdsp.2019.09.322
Date:
January, 2020
File:
PDF, 173 KB
2020